Kenta Biotech Raises Series B
Kenta Biotech, a Switzerland-based developer of human monoclonal antibody therapies for serious hospital infections, has raised CHF 12 million ($10m) in Series B funding. No investor information was fisclosed.
12 March 2009•3 mins read
